Ceryvyn Therapeutics Ltd
OPT
Rank in Stocks
#31872
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Share Price
$0.00846342
Last synced: 2026-07-27
Market Cap
$11.27M
Change (1 day)
0.00%
Change (1 year)
-99.75%
Country
AU
Trade Ceryvyn Therapeutics Ltd (OPT)
Category
Healthcare
Number of shares outstanding for Ceryvyn Therapeutics Ltd (OPT)
Number of shares outstanding as of June 2025: 153.78M
According to Ceryvyn Therapeutics Ltd latest financial reports and stock price the company's current number of shares outstanding is 153.78M. At the end of June 2024 the company had 79.78M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Ceryvyn Therapeutics Ltd (OPT) from 2000 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 153.78M | 0.45% |
| 2025 | 153.09M | 91.90% |
| 2024 | 79.78M | 35.92% |
| 2023 | 58.69M | 25.91% |
| 2022 | 46.62M | 9.71% |
| 2021 | 42.49M | 30.49% |
| 2020 | 32.56M | 11.90% |
| 2019 | 29.10M | 0.27% |
| 2018 | 29.02M | 25.03% |
| 2017 | 23.21M | 7.34% |
| 2016 | 21.62M | 49.48% |
| 2015 | 14.47M | 119.26% |
| 2014 | 6.60M | 8.67% |
| 2013 | 6.07M | -3.84% |
| 2012 | 6.31M | 0.63% |
| 2011 | 6.27M | 2.22% |
| 2010 | 6.14M | 1.38% |
| 2009 | 6.05M | 2.44% |
| 2008 | 5.91M | 0.00% |
| 2007 | 5.91M | 8.57% |
| 2006 | 5.44M | -7.89% |
| 2005 | 5.91M | -0.12% |
| 2004 | 5.92M | 5.63% |
| 2003 | 5.60M | 0.09% |
| 2002 | 5.60M | 7.02% |
| 2001 | 5.23M | 17.30% |
| 2000 | 4.46M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 65.11% |
US
|
|
| 396.00M | 157.51% |
US
|
|
| 478.91M | 211.43% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -59.56% |
NL
|
